Efficacy News and Research

RSS
Women & Infants gets $3M grant to identify infants at greatest risk for developmental impairment

Women & Infants gets $3M grant to identify infants at greatest risk for developmental impairment

Extract from bitter melon may have therapeutic qualities to treat head and neck cancer

Extract from bitter melon may have therapeutic qualities to treat head and neck cancer

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

New hope for patients whose melanoma has metastasised to the brain

New hope for patients whose melanoma has metastasised to the brain

Treatment of pelvic nodes can be easily integrated into IMRT-based treatment strategy

Treatment of pelvic nodes can be easily integrated into IMRT-based treatment strategy

Oraya presents data from INTREPID study of stereotactic radiotherapy for treatment of wet AMD

Oraya presents data from INTREPID study of stereotactic radiotherapy for treatment of wet AMD

GO drug may improve outcome of bone marrow transplantation for select pediatric leukemia patients

GO drug may improve outcome of bone marrow transplantation for select pediatric leukemia patients

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

Research could refine next generation of drugs to help treat dementia

Research could refine next generation of drugs to help treat dementia

New Malaria Vaccine Technology Roadmap aims to identify second generation malaria vaccines

New Malaria Vaccine Technology Roadmap aims to identify second generation malaria vaccines

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

FDA Advisory Committee votes in favor of Vanda's tasimelteon NDA for Non-24-Hour Disorder

FDA Advisory Committee votes in favor of Vanda's tasimelteon NDA for Non-24-Hour Disorder

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Scientists discover new drug mechanism to reduce risk of infections

Scientists discover new drug mechanism to reduce risk of infections

Lower doses of antimalarial drug effective in reducing malaria transmission

Lower doses of antimalarial drug effective in reducing malaria transmission

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

NeuroPace RNS System gets premarket approval from FDA for treatment of partial onset seizures

NeuroPace RNS System gets premarket approval from FDA for treatment of partial onset seizures

Svelte completes enrollment in drug-eluting coronary stent Integrated Delivery System study

Svelte completes enrollment in drug-eluting coronary stent Integrated Delivery System study

Sorrento Therapeutics to acquire San Diego-based Concortis Biosystems

Sorrento Therapeutics to acquire San Diego-based Concortis Biosystems

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.